Carrie B Wiese1, Jianyong Zhong2, Zhi-Qi Xu2, Youmin Zhang3, Marisol A Ramirez Solano4, Wanying Zhu3, MacRae F Linton3, Quanhu Sheng4, Valentina Kon2, Kasey C Vickers5. 1. Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA. 2. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: kasey.c.vickers@vumc.org.
Abstract
BACKGROUND AND AIMS: Cardiovascular disease (CVD) is the leading cause of death in chronic kidney disease (CKD) patients, however, the underlying mechanisms that link CKD and CVD are not fully understood and limited treatment options exist in this high-risk population. microRNAs (miRNA) are critical regulators of gene expression for many biological processes in atherosclerosis, including endothelial dysfunction and inflammation. We hypothesized that renal injury-induced endothelial miRNAs promote atherosclerosis. Here, we demonstrate that dual inhibition of endothelial miRNAs inhibits atherosclerosis in the setting of renal injury. METHODS: Aortic endothelial miRNAs were analyzed in apolipoprotein E-deficient (Apoe-/-) mice with renal damage (5/6 nephrectomy, 5/6Nx) by real-time PCR. Endothelial miR-92a-3p and miR-489-3p were inhibited by locked-nucleic acid (LNA) miRNA inhibitors complexed to HDL. RESULTS: Renal injury significantly increased endothelial miR-92a-3p levels in Apoe-/-;5/6Nx mice. Dual inhibition of miR-92a-3p and miR-489-3p in Apoe-/-;5/6Nx with a single injection of HDL + LNA inhibitors significantly reduced atherosclerotic lesion area by 28.6% compared to HDL + LNA scramble (LNA-Scr) controls. To examine the impact of dual LNA treatment on aortic endothelial gene expression, total RNA sequencing was completed, and multiple putative target genes and pathways were identified to be significantly altered, including the STAT3 immune response pathway. Among the differentially expressed genes, Tgfb2 and Fam220a were identified as putative targets of miR-489-3p and miR-92a-3p, respectively. Both Tgfb2 and Fam220a were significantly increased in aortic endothelium after miRNA inhibition in vivo compared to HDL + LNA-Scr controls. Furthermore, Tgfb2 and Fam220a were validated with gene reporter assays as direct targets of miR-489-3p and miR-92a-3p, respectively. In human coronary artery endothelial cells, over-expression and inhibition of miR-92a-3p decreased and increased FAM220A expression, respectively. Moreover, miR-92a-3p overexpression increased STAT3 phosphorylation, likely through direct regulation of FAM220A, a negative regulator of STAT3 phosphorylation. CONCLUSIONS: These results support endothelial miRNAs as therapeutic targets and dual miRNA inhibition as viable strategy to reduce CKD-associated atherosclerosis.
BACKGROUND AND AIMS: Cardiovascular disease (CVD) is the leading cause of death in chronic kidney disease (CKD) patients, however, the underlying mechanisms that link CKD and CVD are not fully understood and limited treatment options exist in this high-risk population. microRNAs (miRNA) are critical regulators of gene expression for many biological processes in atherosclerosis, including endothelial dysfunction and inflammation. We hypothesized that renal injury-induced endothelial miRNAs promote atherosclerosis. Here, we demonstrate that dual inhibition of endothelial miRNAs inhibits atherosclerosis in the setting of renal injury. METHODS: Aortic endothelial miRNAs were analyzed in apolipoprotein E-deficient (Apoe-/-) mice with renal damage (5/6 nephrectomy, 5/6Nx) by real-time PCR. Endothelial miR-92a-3p and miR-489-3p were inhibited by locked-nucleic acid (LNA) miRNA inhibitors complexed to HDL. RESULTS:Renal injury significantly increased endothelial miR-92a-3p levels in Apoe-/-;5/6Nx mice. Dual inhibition of miR-92a-3p and miR-489-3p in Apoe-/-;5/6Nx with a single injection of HDL + LNA inhibitors significantly reduced atherosclerotic lesion area by 28.6% compared to HDL + LNA scramble (LNA-Scr) controls. To examine the impact of dual LNA treatment on aortic endothelial gene expression, total RNA sequencing was completed, and multiple putative target genes and pathways were identified to be significantly altered, including the STAT3 immune response pathway. Among the differentially expressed genes, Tgfb2 and Fam220a were identified as putative targets of miR-489-3p and miR-92a-3p, respectively. Both Tgfb2 and Fam220a were significantly increased in aortic endothelium after miRNA inhibition in vivo compared to HDL + LNA-Scr controls. Furthermore, Tgfb2 and Fam220a were validated with gene reporter assays as direct targets of miR-489-3p and miR-92a-3p, respectively. In human coronary artery endothelial cells, over-expression and inhibition of miR-92a-3p decreased and increased FAM220A expression, respectively. Moreover, miR-92a-3p overexpression increased STAT3 phosphorylation, likely through direct regulation of FAM220A, a negative regulator of STAT3 phosphorylation. CONCLUSIONS: These results support endothelial miRNAs as therapeutic targets and dual miRNA inhibition as viable strategy to reduce CKD-associated atherosclerosis.
Authors: Fatiha Tabet; Kasey C Vickers; Luisa F Cuesta Torres; Carrie B Wiese; Bassem M Shoucri; Gilles Lambert; Claire Catherinet; Leonel Prado-Lourenco; Michael G Levin; Seth Thacker; Praveen Sethupathy; Philip J Barter; Alan T Remaley; Kerry-Anne Rye Journal: Nat Commun Date: 2014-02-28 Impact factor: 14.919
Authors: Andrew H J Salmon; Joanne K Ferguson; James L Burford; Haykanush Gevorgyan; Daisuke Nakano; Steven J Harper; David O Bates; Janos Peti-Peterdi Journal: J Am Soc Nephrol Date: 2012-07-12 Impact factor: 10.121
Authors: Jean-Claude Tardif; Christie M Ballantyne; Philip Barter; Jean-Louis Dasseux; Zahi A Fayad; Marie-Claude Guertin; John J P Kastelein; Constance Keyserling; Heather Klepp; Wolfgang Koenig; Philippe L L'Allier; Jacques Lespérance; Thomas F Lüscher; John F Paolini; Ahmed Tawakol; David D Waters Journal: Eur Heart J Date: 2014-04-29 Impact factor: 29.983
Authors: Anne M Hüsing; Vera C Wulfmeyer; Svenja Gaedcke; Susanne V Fleig; Song Rong; David DeLuca; Hermann Haller; Roland Schmitt; Sibylle von Vietinghoff Journal: J Am Soc Nephrol Date: 2022-05-10 Impact factor: 14.978